Remove 2027 Remove Competition Remove Leads
article thumbnail

Consequences of the First 10 Drugs Selected for Medicare’s Negotiation Program

PM360

They do not have biosimilar or generic competition available in the market. Additionally, highly competitive classes, such as rapid-acting insulin and immunologics are included on the selected drug list. CMS negotiation may lead to additional savings for beneficiaries and for the Medicare program.

article thumbnail

Horizon Europe deal signals UK research reinvigoration

European Pharmaceutical Review

Researchers can apply for grants and bid to take part in projects with certainty that the UK will be participating as a fully associated member until the deal reaches its end in 2027.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

European PFAS restriction could jeopardise pharmaceutical manufacturing

European Pharmaceutical Review

EMA prepares for winter antibiotic shortages PFAS restriction in pharmaceutical manufacturing In its current form, the procedure currently underway could lead to a ban on all PFASs by 2027, with very limited derogations, EFPIA acknowledged.

article thumbnail

The Top 10 Clinical Research Companies in the USA

Medico Reach

billion , and by 2027, it is expected to reach around an exciting amount of 115.1 from 2022 to 2027. CROs play a critical role in the pharmaceutical, biotech, and medical device industries to manage and lead their clinical trials now more than ever due to rapidly rising prices, regulations, and tighter deadlines.

article thumbnail

Nine for 2023, part two: healthcare’s hard problem, the prognosis for diagnosis, and key new pharmacotherapy platforms

pharmaphorum

This is definitely not because all unmet need is addressed: the WHO reports that the three leading causes of death globally, and growing, are ischaemic heart disease, stroke, and chronic obstructive pulmonary disease. Alzheimer’s is currently the seventh-leading cause of death globally and growing fast. About the author.

FDA 98
article thumbnail

Navigating the rapidly changing oncology treatment landscape: how digital tools can help

Impetus Digital

In 2022, global spending on cancer medicines was approximately 196 billion USD, and this number is forecasted to reach $375 billion by 2027. Increased competition and evolving standard of care New competitors are entering the market at a rapid pace, and competition is intensifying. However, with rapid growth comes growing pains.

article thumbnail

Sales Strategy For Milk Products Insights

Contrarian Sales Techniques

By focusing on the benefits, you are more likely to make a strong emotional connection with your prospects, which can lead to a sale. This is what sets your product apart from the competition and gives your customers a reason to choose your product over others. billion by 2027, growing at a CAGR of 7.7% from 2020 to 2027.